310 related articles for article (PubMed ID: 33012268)
1. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
2. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
3. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
[No Abstract] [Full Text] [Related]
4. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
5. Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
Xu M; Casio M; Range DE; Sosa JA; Counter CM
Clin Cancer Res; 2018 Sep; 24(17):4271-4281. PubMed ID: 30065097
[No Abstract] [Full Text] [Related]
6. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
7. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
8. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Exp Mol Pathol; 2015 Dec; 99(3):492-7. PubMed ID: 26403329
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
[TBL] [Abstract][Full Text] [Related]
10. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
[TBL] [Abstract][Full Text] [Related]
11. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
12. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
13. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
14. BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.
Zerilli M; Zito G; Martorana A; Pitrone M; Cabibi D; Cappello F; Giordano C; Rodolico V
Mod Pathol; 2010 Aug; 23(8):1052-60. PubMed ID: 20473281
[TBL] [Abstract][Full Text] [Related]
15. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
16. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W
Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586
[TBL] [Abstract][Full Text] [Related]
17. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.
Dultz LA; Dhar S; Ogilvie JB; Heller KS; Bar-Sagi D; Patel KN
Surgery; 2013 Dec; 154(6):1239-44; discussion 1244-5. PubMed ID: 24094449
[TBL] [Abstract][Full Text] [Related]
18. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
19. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
20. Circulating BRAF
Lubitz CC; Zhan T; Gunda V; Amin S; Gigliotti BJ; Fingeret AL; Holm TM; Wachtel H; Sadow PM; Wirth LJ; Sullivan RJ; Panka DJ; Parangi S
Thyroid; 2018 Mar; 28(3):328-339. PubMed ID: 29378474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]